Evidence map›Paper›PMID 11113199›Full record

ArticleMolecular and cellular biology2001

Biochemical and biological functions of the N-terminal, noncatalytic domain of extracellular signal-regulated kinase 2.

S T Eblen, A D Catling, M C Assanah, M J Weber

Open access · greenAbstract read
In one paragraph

Article in Molecular and cellular biology, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 59 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

S T EblenDepartment of Microbiology and Cancer Center, School of Medicine, University of Virginia, Charlottesville, Virginia 22908, USA.
A D Catling
M C Assanah
M J Weber
University of Virginia · US

Funding

STRUCTURE AND FUNCTION OF A CELLULAR TYROSINE PROTEIN KINASEP01CA040042 · NCI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI PARSONS, THOMAS J · 1985 to 2009
$10.5M
P42/MAP KINASE: STRUCTURE, FUNCTION AND REGULATIONR01GM047332 · NIGMS · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI WEBER, MICHAEL J · 1992 to 2000
$227k
MAP KINASE NUCLEAR SIGNALING AND TRANSLOCATIONF32GM018672 · NIGMS · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI EBLEN, SCOTT T · 1997 to 1998
–
NCI NIH HHS CA40042NCI NIH HHS P01 CA040042NIGMS NIH HHS 5F32 GM18672-02NIGMS NIH HHS F32 GM018672NIGMS NIH HHS GM47332
6 · The paper itself

Abstract

Extracellular signal-regulated kinase 1 (ERK1) and ERK2 are important components in signal transduction pathways involved in many cellular processes, including cell differentiation and proliferation. These proteins consist of a central kinase domain flanked by short N- and C-terminal noncatalytic domains. While the regulation of ERK2 by sequences within the kinase domain has been extensively studied, little is known about the small regions outside of the kinase domain. We performed mutational analysis on the N-terminal, noncatalytic domain of ERK2 in an attempt to determine its role in ERK2 function and regulation. Deleting or mutating amino acids 19 to 25 (ERK2-Delta19-25) created an ERK2 molecule that could be phosphorylated in response to growth factor and serum stimulation in a MEK (mitogen-activated protein kinase kinase or ERK kinase)-dependent manner but had little kinase activity and was unable to bind to MEK in vivo. Since MEK acts as a cytoplasmic anchor for the ERKs, the lack of a MEK interaction resulted in the aberrant nuclear localization of ERK2-Delta19-25 mutants in serum-starved cells. Assaying these mutants for their ability to affect ERK signaling revealed that ERK2-Delta19-25 mutants acted in a dominant-negative manner to inhibit transcriptional signaling through endogenous ERKs to an Elk1-responsive promoter in transfected COS-1 cells. However, ERK2-Delta19-25 had no effect on the phosphorylation of RSK2, an ERK2 cytoplasmic substrate, whereas a nonactivatable ERK (T183A) that retained these sequences could inhibit RSK2 phosphorylation. These results suggest that the N-terminal domain of ERK2 profoundly affects ERK2 localization, MEK binding, kinase activity, and signaling and identify a novel dominant-negative mutant of ERK2 that can dissociate at least some transcriptional responses from cytoplasmic responses.

Indexed as

DNA-Binding ProteinsRibosomal Protein S6 Kinases, 90-kDaTranscription FactorsAmino Acid SequenceAnimalsCell NucleusCOS CellsCulture Media, Serum-FreeCytoplasmets-Domain Protein Elk-1Fluorescent Antibody TechniqueGene Expression RegulationGenes, ReporterMAP Kinase Signaling SystemMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase KinasesCulture Media, Serum-FreeDNA-Binding Proteinsets-Domain Protein Elk-1Mitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase KinasesMitogen-Activated Protein KinasesPeptide FragmentsProto-Oncogene ProteinsRecombinant Fusion ProteinsRibosomal Protein S6 KinasesRibosomal Protein S6 Kinases, 90-kDaTranscription Factors

Identifiers

PMID11113199
PMCPMC88798
OpenAlexW2097569409

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.